Journal: APL Bioengineering

Article Title: Trans-septal delivery of hydrogel-encapsulated human umbilical cord MSC-derived neurospheres for acute neuroprotection in traumatic brain injury

doi: 10.1063/5.0288289

Figure Lengend Snippet: Neuroprotective effects of trans-septal transplantation of HMNS following TBI. (a) Representative images show tissue samples stained for BDNF and NeuN markers 7 days after TBI. Scale bar, 20 μm. (b) Quantification of BDNF intensity in the CA1 region of the ipsilateral hippocampus stained for mature BDNF. (c)–(e) Immunostaining with NeuN antibody revealed the distribution of live neurons in the ipsilateral hippocampal CA1 region. Scale bar, 50 μm. (f)–(j) Quantification of the number of NeuN+ neurons from each hippocampal area. Data for all quantifications are presented as mean ± SEM (n = 3 for sham, n = 6 for TBI groups). Statistical significance was determined by one-way ANOVA followed by Tukey's post hoc test. *p < 0.05 vs the hydrogel-only group.

Article Snippet: The antibodies used in this study included MAP2 (1:500, Abcam), 4-HNE (1:500, Alpha Diagnostic International), nitrotyrosine (1:500, Abcam), BDNF (1:400, Alomone Labs), and NeuN (1:500, Millipore).

Techniques: Transplantation Assay, Staining, Immunostaining

Journal: bioRxiv

Article Title: Lactate treatment improves brain biochemistry and cognitive function in transgenic Alzheimer’s and wild-type mice

doi: 10.64898/2026.01.28.702254

Figure Lengend Snippet: Relative mRNA expression levels of hydroxycarboxylic acid receptor 1 ( Hcar1 ), monocarboxylate transporter 2 ( Mct2, Slc16a7 ), Vascular endothelial growth factor ( Vegfa ), Brain-derived neurotrophic factor ( Bdnf ), and Insulin-like growth factor 1 ( Igf1 ) were quantified by RT-qPCR using the 2 ⁻ΔΔCt method in 5XFAD transgenic (Tg) and wild-type (WT) mice treated with lactate or vehicle. Tg lactate ( n = 10), Tg vehicle ( n = 11), WT lactate ( n = 7), and WT vehicle ( n = 8). Groups included both sexes and combined early- and late-treatment start cohorts. (a) Hcar1 expression showed a modest increase following lactate treatment in WT mice; however, no significant differences were observed in any of the groups. (b) Lactate administration significantly increased Mct2 expression in WT mice compared to vehicle-treated controls ( p = 0.021, d = 1.26). No significant changes were observed in Tg mice treated with lactate versus vehicle. (c) Bdnf expression was significantly higher in WT mice receiving lactate compared to vehicle-treated WT controls ( p < 0.001, d = 2.14). (d) Igf1 expression was significantly upregulated in WT mice receiving lactate compared to WT controls ( p = 0.033, d = 1.16). (e) Vegfa expression was significantly upregulated in lactate-treated WT mice compared to vehicle-treated WT controls ( p = 0.004, d = 1.60). Data are presented as individual data points, with statistical analyses performed using one-way ANOVA, followed by Fisher’s least significant test (LSD). Results are displayed as mean ± standard deviation (SD).

Article Snippet: Genes of interest, including Bdnf (Mm01334042_m1), Hcar1 (Mm00558586_s1), Igf1 (Mm00439560_m1), Il1b (Mm00434228_m1), Il4 (Mm00445259_m1), Il13 (Mm00434204_m1), Slc16a7 (Mct2) (Mm00441442_m1), Vegfa (Mm00437306_m1), were assessed.

Techniques: Expressing, Derivative Assay, Quantitative RT-PCR, Transgenic Assay, Standard Deviation

Journal: medRxiv

Article Title: Identification of serum protein biomarkers in individuals with Niemann-Pick disease, type C1

doi: 10.64898/2026.01.12.26343721

Figure Lengend Snippet: Identification and validation of differentially abundant proteins in NPC1 serum: (a) Volcano plot of differentially abundant proteins comparing NPX values of NPC1 individuals at baseline not receiving miglustat compared to healthy pediatric control, Proteins with adjusted p-value < 0.1 and adjusted log2FC +1 and −1 were considered increased and decreased, respectively. All the proteins with adjusted p-values <0.1 are highlighted in red and proteins selected for validation are labelled. ELISA validation of expression levels of (b) TREM2, (c) AgRP, (d) NPY, (e) HSD17B14, (f) GPNMB, (g) Cathepsin L, (h) CCL18, and (i) BDNF.

Article Snippet: Serum BDNF levels were measured using SimoaTM BDNF discovery kit (Item 102039) on the Quanterix SR-X platform in a 96-well plate format (Quanterix, Billerica, MA, USA).

Techniques: Biomarker Discovery, Control, Enzyme-linked Immunosorbent Assay, Expressing

Journal: medRxiv

Article Title: Identification of serum protein biomarkers in individuals with Niemann-Pick disease, type C1

doi: 10.64898/2026.01.12.26343721

Figure Lengend Snippet: Spearman Correlation of clinical parameters with ELISA (a) TREM with Age of neurological onset, (b) GPNMB with age of neurological onset, (c) GPNMB with Annual Severity Increment score, (d) GPNMB serum levels in male and female NPC1 individuals, and (e) BDNF correlation with Age of neurological onset. Spearman correlations with rho-values of 0.1-0.3, 0.3-0.5, and >0.5 and p-value < 0.05 were considered weak, moderate, and strong, respectively. An unpaired two-tailed t-test was used to evaluate the differences in GPNMB serum levels between males and females.

Article Snippet: Serum BDNF levels were measured using SimoaTM BDNF discovery kit (Item 102039) on the Quanterix SR-X platform in a 96-well plate format (Quanterix, Billerica, MA, USA).

Techniques: Enzyme-linked Immunosorbent Assay, Two Tailed Test